In patients who receive neoadjuvant pembrolizumab and chemotherapy for TNBC, how will you manage adjuvant treatment if they have a germline BRCA mutation?

For patients with clinically high risk early TNBC and germline PV in BRCA 1 or 2 undergoing neoadjuvant chemotherapy along with pembrolizumab, the course of adjuvant therapy will depend on pathologic response at surgery.

For those with pCR - I would continue adjuvant pembrolizumab for patients who ar...

Olaparib is not approved for use as adjuvant therapy for breast cancer. If the patient was treated with NAC and pembrolizumab, I would continue pembrolizumab in the adjuvant setting, per published and FDA-approved protocol. It is not yet known whether patients who are treated with NAC and pembrolizu...

Based on the KEYNOTE-522 study, neoadjuvant pembrolizumab with chemotherapy followed by adjuvant pembrolizumab for triple negative breast cancer patients with either a more than 2 cm primary or lymph node positive disease became standard of care. Based on the updated results from the study (ESMO 202...

The rate of pathologic complete response with chemotherapy is higher in gBRCA1m and/or gBRCA2m carriers with TNBC than in nonmutation carriers. The results of the KEYNOTE-522 trial by BRCA status are not available. One might first question the role of neoadjuvant pembrolizumab in this setting. Howev...

Both